BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 28893134)

  • 1. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
    Pavord ID; Chanez P; Criner GJ; Kerstjens HAM; Korn S; Lugogo N; Martinot JB; Sagara H; Albers FC; Bradford ES; Harris SS; Mayer B; Rubin DB; Yancey SW; Sciurba FC
    N Engl J Med; 2017 Oct; 377(17):1613-1629. PubMed ID: 28893134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.
    Pavord ID; Chapman KR; Bafadhel M; Sciurba FC; Bradford ES; Schweiker Harris S; Mayer B; Rubin DB; Yancey SW; Paggiaro P
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1755-1770. PubMed ID: 34163157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
    Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
    N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benralizumab for the Prevention of COPD Exacerbations.
    Criner GJ; Celli BR; Brightling CE; Agusti A; Papi A; Singh D; Sin DD; Vogelmeier CF; Sciurba FC; Bafadhel M; Backer V; Kato M; Ramírez-Venegas A; Wei YF; Bjermer L; Shih VH; Jison M; O'Quinn S; Makulova N; Newbold P; Goldman M; Martin UJ; ;
    N Engl J Med; 2019 Sep; 381(11):1023-1034. PubMed ID: 31112385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
    Criner GJ; Celli BR; Singh D; Agusti A; Papi A; Jison M; Makulova N; Shih VH; Brooks L; Barker P; Martin UJ; Newbold P
    Lancet Respir Med; 2020 Feb; 8(2):158-170. PubMed ID: 31575508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
    Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
    Pavord ID; Korn S; Howarth P; Bleecker ER; Buhl R; Keene ON; Ortega H; Chanez P
    Lancet; 2012 Aug; 380(9842):651-9. PubMed ID: 22901886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
    N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia.
    Condreay LD; Gao C; Bradford E; Yancey SW; Ghosh S
    Respir Med; 2019 Aug; 155():26-28. PubMed ID: 31295674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH; Wenzel SE; Thompson PJ; Prazma CM; Keene ON; Yancey SW; Ortega HG; Pavord ID;
    N Engl J Med; 2014 Sep; 371(13):1189-97. PubMed ID: 25199060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations.
    Fernandez Romero GA; Beros J; Criner G
    Expert Rev Respir Med; 2019 Feb; 13(2):125-132. PubMed ID: 30570418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab and exacerbations of refractory eosinophilic asthma.
    Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
    N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.